SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $115 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $765 | $822 | $778 | $786 |
| Gross Profit | -$765 | -$822 | -$778 | -$671 |
| % Margin | – | – | – | -585% |
| R&D Expenses | $8,948 | $6,997 | $7,636 | $7,630 |
| G&A Expenses | $0 | $2,735 | $0 | $0 |
| SG&A Expenses | $2,965 | $2,735 | $2,358 | $1,708 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$822 | $0 | $0 |
| Operating Expenses | $11,914 | $8,910 | $9,994 | $9,338 |
| Operating Income | -$12,679 | -$9,732 | -$10,772 | -$10,009 |
| % Margin | – | – | – | -8,726.3% |
| Other Income/Exp. Net | $58,124 | -$382 | $5,575 | -$1,386 |
| Pre-Tax Income | $45,445 | -$10,114 | -$5,197 | -$11,395 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $5,338 | -$10,114 | -$5,197 | -$11,395 |
| % Margin | – | – | – | -9,934.5% |
| EPS | 0.5 | -1.09 | -0.56 | -1.23 |
| % Growth | 145.9% | -94.6% | 54.5% | – |
| EPS Diluted | -0.21 | -1.09 | -0.56 | -1.23 |
| Weighted Avg Shares Out | 10,661 | 9,294 | 9,292 | 9,262 |
| Weighted Avg Shares Out Dil | 77,863 | 9,294 | 9,292 | 9,262 |
| Supplemental Information | – | – | – | – |
| Interest Income | $655 | $14 | $62 | $136 |
| Interest Expense | $43 | $64 | $70 | $71 |
| Depreciation & Amortization | $765 | $822 | $778 | $786 |
| EBITDA | $46,254 | -$9,228 | -$4,349 | -$10,538 |
| % Margin | – | – | – | -9,187.7% |